GalOmic™
SELECTIVELY SILENCING DISEASE
—GalOmic enables the generation of our potent and long-acting RNAi medicines. It’s the culmination of our proprietary siRNA chemistry knowledge.
Cell specificity
SCIENCE THAT’S TARGETED
GalOmic is designed for precise and reliable liver-targeted delivery. Our proprietary GalNAc conjugates guide siRNA directly to hepatocytes, ensuring high specificity while minimizing exposure to other cell types. This targeted approach enhances safety, optimizes therapeutic activity, and enables convenient subcutaneous dosing. Built on proven chemistries, GalOmic provides a robust foundation for effective RNAi medicines.
The role of the liver
SCIENCE THAT UNLOCKS POTENTIAL
The liver is central to human health and linked to a wide range of diseases with high unmet need. Hepatocytes don’t just influence liver health. They drive biological processes that influence a wide range of diseases across the body. With over 12,000 genes expressed in hepatocytes, the opportunity for GalOmic therapies is vast.
GalOmic medicines harness this potential. They target hepatocytes with precision, delivering therapies exactly where they are needed. Powered by LLibra, we can identify differentiated targets that extend far beyond liver diseases. GalOmic medicines can unlock new possibilities for patients across multiple disease areas.
siRNA therapies
SCIENCE THAT MOVES FASTER
GalOmic medicines are built for speed, reliability, and reproducibility. They are inherently modular. Once a sequence is designed, it can be adapted and optimized with efficiency. Our AI-driven approach streamlines the design process, allowing us to move directly to in vivo experiments and accelerate development. We do not start from scratch with every new program. We build on proven principles to move from target identification to the clinic in less than three years.
